Top Markets
#1 Purr Purr +56.58%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +46.97%
#4 Non-Playable Coin Non-Playable Coin +29.18%
#5 StonkBroker StonkBroker +28.69%
#6 ApeX ApeX +25.25%
#7 Kinetiq Kinetiq +24.62%
#8 TENDIES TENDIES +24.06%
#9 Morpho Morpho +21.83%
#10 OriginTrail OriginTrail +21.30%
Coin of the day
Purr Purr
設定
言語
日本
通貨
USD
テーマ
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
株式のランク #21013
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
株価
$7.12
最終同期: 2023-03-08
時価総額
$117.03M
変化（1日）
0.00%
変化（1年）
0.00%
国
GB
取引 F-star Therapeutics, Inc. (FSTX)

カテゴリー

Healthcare
F-star Therapeutics, Inc.（FSTX）の収益
Aug 2026 時点の収益 TTM: 0
F-star Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
F-star Therapeutics, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH